USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK
https://doi.org/10.14412/1995-4484-2017-321-323
Abstract
The paper discusses the specific features of using nonsteroidal anti-inflammatory drugs in patients with high cardiovascular risk.
About the Author
Yu. A. Olyunin
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000 Nov 23;343(21):1520-8. doi: 10.1056/NEJM200011233432103
2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247
3. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. doi: 10.1056/NEJMoa050405
4. Bavry AA, Thomas F, Allison M, et al. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative. Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):603-10. doi: 10.1161/CIRCOUTCOMES.113.000800
5. Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140- 6736(13)60900-9
6. Solomon SD, Wittes J, Finn PV, et al; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22;117(16):2104-13. doi: 10.1161/CIRCULATIONAHA.108.764530
7. Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23
8. Nissen SE, Yeomans ND, Solomon DH, et al; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519- 29. doi: 10.1056/NEJMoa1611593
Review
For citations:
Olyunin Yu.A. USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. Rheumatology Science and Practice. 2017;55(3):321-323. (In Russ.) https://doi.org/10.14412/1995-4484-2017-321-323
Views:
654
Email this article 